The probability of revision sinus surgery including removing nasal polyps is higher if the patient has asthma or is on ...

The probability of revision sinus surgery including the removal of nasal polyps is higher if the patient has asthma or is on antibiotics at the time of their initial surgery. However, higher age was ...

The decision to remove or not remove a polyp is based on the size of the growth as well as its location and appearance. But usually, the only polyps that are not removed are very small, definitely ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

December 05, 2024--AstraZeneca’s IMFINZI® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell ... with nasal polyps (CRSwNP [nasal polyps ...

The global laser-assisted ENT surgery market Share is projected to grow from US$ 254.14 million in 2023 to US$ 513.78 million ...

Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...

Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis, chronic rhinosinusitis without ...

Amy Danise is the managing editor for the insurance section at Forbes Advisor, which encompasses auto, home, renters, life, pet, travel, health and small business insurance. She is a highly ...

When interest rates are low, small-cap stocks begin to shine and outpace larger companies in value. These stocks are stocks with a market capitalization between $300 million and $3 billion.

The probability of revision sinus surgery including the removal of nasal polyps is higher if the patient has asthma or is on antibiotics at the time of their initial surgery. However, higher age ...

IPC Indice de Precios Y Cotizaciones 51,889.75 680.22 1.33% ...